Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects

Diabetic Medicine

Volumn 16, Issue 10, 1999, Pages 867-874

  Ørskov, Lotto ^a,b   Nyholm, B ^a   Yde Hove, K ^a   Gravholt, C H ^b   Moller N ^a   Schmitz, O ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Glucagon; Insulin; Intermediary metabolism; Pramlintide; Type 1 diabetes mellitus

Indexed keywords

ADRENALIN; AMYLIN DERIVATIVE; GLUCAGON; GLUCOSE; GLYCOGEN; GROWTH HORMONE; HYDROCORTISONE; NEUTRAL INSULIN; NORADRENALIN; PRAMLINTIDE; SOMATOSTATIN;

ADRENALIN BLOOD LEVEL; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES CONTROL; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; GLYCOGEN METABOLISM; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; NORADRENALIN BLOOD LEVEL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0032706092     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00164.x     Document Type: Article

References (32)

1. 13C nuclear magnetic resonance spectroscopy study. J Clin Invest 1997; 95: 783-787.
2. 2 Ørskov L, Alberti KGMM, Mengel A, Meller N, Pederson O, Rasmussen O et al. Decreased hepatic glucagon responses in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1991; 34: 521-526.
3. 3 Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG. Amylin concentrations and glucose control. Lancet 1992; 339: 1179-1180.
4. 4 Young AA, Crocker LB, Wolfe-Lopez D, Cooper GJS. Daily amylin replacement reverses hepatic glycogen depletion in insulin-treated streptozocin diabetic rats. FEBS 1991; 287: 203-205.
5. 5 Thompson RG, Peterson J, Gottlieb A, Mullane J. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM. results of a multicenter trial. Diabetes 1997; 46: 632-636.
6. 6 Nyholm B, Ørskov L, Hove K et al. The amylin analogue pramlintide improves glycaemic control and reduces post-prandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism 1995; 48: 935-941.
7. 7 Fineman F, Kolterman O, Thompson R, Koda J. The human amylin analogue pramlintide inhibited glucagon secretion in type 1 diabetic subjects. Diabetes 1997; 46: A0117.
8. 8 Kong M-F, King P, Macdonald A, Stubbs TA, Perkins AC, Blackshaw PE et al. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia 1997; 40: 82-88.
9. 9 Young A, Denaro M. Role of amylin in diabetes and in regulation of nutrient load. Nutrition 1998; 14: 524-7.
10. 10 Wilding JP, Khandan Nia N, Nia N, Bennet WM, Gilbey SG, Beacham J et al. Lack of acute effect of amylin (islet-associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans. Diabetologia 1994; 37: 166-169.
11. 11 Kolterman OG, Moyses C, Gottlieb A, Colburn W. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Diab Care 1995; 18: 1179-1182.
12. 12 Leighton B, Cooper GJS. Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature 1988; 335: 632-635.
13. 13 Kassir AA, Upadhyay AK, Lim TJ, Moossa AR, Olefsky JM. Lack of effect of islet amyloid polypeptide in causing insulin resistance in conscious dogs during euglycemic clamp studies. Diabetes 1991; 40: 998-1004.
14. 14 Nyholm B, Møller N, Gravholt CH, Ørskov L, Mengel A, Bryan G et al. Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 1083-1089.
15. 15 Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J et al. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 1996; 39: 492-499.
16. 16 Ørskov L, Holst JJ, Møller J, Ørskov C, Møller N et al. GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 1996; 39: 1227-1232.
17. 17 Møller N, Butler PC, Antsiferov M, Alberti KGMM. Effects of growth hormone on insulin sensitivity and forearm metabolism in normal man. Diabetologia 1989; 32: 105-110.
18. 18 Ørskov L, Bak JF, Abildgard N, Schmitz O, Andreasen F et al. Inhibition of muscle glycogen synthase activity and non-oxidative glucose disposal during hypoglycaemia in normal man. Diabetologia 1996; 39: 226-234.
19. 19 Forster CD, Taylor JY, Macdonald IA. Monitoring molecules in neuroscience: the assay of the catecholamine content of small volumes of human plasma. Gronningen: University of Gronningen, 1991; 173-175.
20. 20 Finegood DT, Bergman RN, Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Diabetes 1987; 36: 914-924.
21. 21 Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 1983; 55: 628-634.
22. 22 Lefebvre PJ. Glucagon and its family revisited. Diabetes Care 1995; 18: 715-730.
23. 23 Cherrington A-D. The metabolic actions of glucagon. In Braznin D and Rizza R eds. Clinical Research in Diabetes and Obesity, Part I. Methods, Assesment, and Metabolic Regulation. Totowa, NJ: Humana Press Inc., 1997; 221-242.
24. 24 Gerich J, Landlois M, Noacco C, Karam J, Forsharn P. Lack of glucagon response to hypoglycemia in diabetes. Science 1973; 182: 171-173.
25. 25 Unger RH. Role of glucagon in the pathogenesis of diabetes: the status of the controversy. Metabol 1978; 27: 1691-1709.
26. 26 Dinneen S, Alzaid A, Turk D, Rizza R. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 1995; 38: 337-343.
27. 27 Young AA, Wang MW, Cooper GJ. Amylin injection causes elevated plasma lactate and glucose in the rat. FEBS Lett 1991; 291: 101-104.
28. 28 Stevenson RW, Steiner KE, Davis MA, Hendrick GK, Williams PE, Lacy WW et al. Similar dose responsiveness of hepatic glycogenolysis and gluconeogenesis to glucagon in vivo. Diabetes 1987; 36: 382-389.
29. 29 Cherrington AD, Diamond MP, Green DR, Williams PE. Evidence for an intrahepatic contribution to the waning effect of glucagon on glucose production in the conscious dog. Diabetes 1982; 31: 917-922.
30. 30 Young AA, Mott DM, Stone K, Cooper GJ. Amylin activates glycogen phosphorylase in the isolated soleus muscle of the rat. FEBS Lett 1991; 281: 149-151.
31. 31 Blackard WG, Clore JN, Kellum JM. Amylin/insulin secretory ratios in morbidly obese man: inverse relationship with glucose disappearance rate. J Clin Endocrinol Metab 1994; 78: 1257-1260.
32. 32 Randle PJ, Hales CN, Garland PB, Newsholme EA. The glucose fatty-acid cycle its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1: 785-789.